Sugi Predict

Sugi Predict / Targets / CDK4

CDK4

Cyclin-dependent kinase 4 · P11802 · CDK4 on Sugi Atlas →

203,427 patent compounds predicted against CDK4, 118,321 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL189662 SCHEMBL189662 1.00 20/20
SCHEMBL188565 SCHEMBL188565 0.53 20/20
SCHEMBL189845 SCHEMBL189845 0.55 19/20
SCHEMBL189897 SCHEMBL189897 0.53 19/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 12/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 12/20
SCHEMBL188528 SCHEMBL188528 0.60 12/20
SCHEMBL189169 SCHEMBL189169 0.55 11/20
SCHEMBL110212 SCHEMBL110212 0.67 10/20
SCHEMBL188747 SCHEMBL188747 0.52 10/20
SCHEMBL31622 SCHEMBL31622 0.51 10/20
SCHEMBL188449 SCHEMBL188449 0.51 10/20
SCHEMBL111391 SCHEMBL111391 0.73 8/20
SCHEMBL110695 SCHEMBL110695 0.73 8/20
SCHEMBL12292 SCHEMBL12292 0.59 8/20
SCHEMBL12466 SCHEMBL12466 0.57 8/20
SCHEMBL137707 SCHEMBL137707 0.57 8/20
SCHEMBL1801 SCHEMBL1801 0.56 8/20
SCHEMBL112928 SCHEMBL112928 0.72 7/20
SCHEMBL1886 SCHEMBL1886 0.62 7/20

Clinical trials — most relevant to CDK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer PHASE4NOT_YET_RECRUITING
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients PHASE3RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) PHASE3COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO PHASE2COMPLETED
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) PHASE2COMPLETED
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. PHASE1/PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer PHASE1/PHASE2RECRUITING
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping PHASE2NOT_YET_RECRUITING
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer PHASE1COMPLETED
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? nanUNKNOWN
The SONImage Study nanACTIVE_NOT_RECRUITING
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CDK4 binder may also engage these)

ProteinNameSimilarity
P79432 — 1.000 P79432 →
Q32KY4 — 1.000 Q32KY4 →
P30285 — 1.000 P30285 →
P35426 — 1.000 P35426 →
B2MVY4 — 1.000 B2MVY4 →
Q38774 — 0.992 Q38774 →
CDK6 Cyclin-dependent kinase 6 0.991 landscape →
Q9JHU3 — 0.990 Q9JHU3 →
CDK20 Cyclin-dependent kinase 20 0.988 landscape →
P54665 — 0.988 P54665 →
Q8L4P8 — 0.988 Q8L4P8 →
P54666 — 0.987 P54666 →
Q64261 — 0.987 Q64261 →
Q91727 — 0.987 Q91727 →
P54119 — 0.987 P54119 →
Q8SW92 — 0.987 Q8SW92 →
P38973 — 0.987 P38973 →
Q4KM34 — 0.987 Q4KM34 →
P54664 — 0.986 P54664 →
Q00646 — 0.986 Q00646 →
Q06309 — 0.986 Q06309 →
Q5R7I7 — 0.986 Q5R7I7 →
Q38775 — 0.986 Q38775 →
Q0J4I1 — 0.985 Q0J4I1 →
Q8LF80 — 0.985 Q8LF80 →
A8WIP6 — 0.985 A8WIP6 →
P25859 — 0.985 P25859 →
P51166 — 0.985 P51166 →
Q03114 — 0.985 Q03114 →
P51952 — 0.984 P51952 →